Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome, a biopharmaceutical firm (Nasdaq: IMNM), has isolated potent antibodies that neutralize multiple SARS-CoV-2 variants through its memory B cell platform. This discovery is part of a broader effort to create a therapeutic antibody cocktail for COVID-19. The identified antibodies bind to various regions of the spike protein, including those in the South African Variant (B.1.351). The research aims to counteract vaccine resistance and potentially enhance viral clearance. Immunome's COVID program is supported by a $13.3 million grant from the U.S. Department of Defense.
Immunome (Nasdaq: IMNM) has partnered with Abzena to develop IMM-BCP-01, an investigational antibody cocktail targeting COVID-19. This collaboration is aimed at producing the cocktail for clinical testing. In July 2020, Immunome received $13.3 million from the U.S. Department of Defense to support this initiative. Both companies emphasize the potential benefits of this therapy in combating the pandemic. Immunome focuses on developing first-in-class therapeutic antibodies utilizing its proprietary human memory B cell platform.
Immunome, Inc. (Nasdaq: IMNM) announced findings from its preclinical COVID-19 research, highlighting the role of non-Spike antibodies in virus clearance. Key results show over 50% of antibodies from super-responders target non-Spike antigens, including nucleocapsid proteins and ORF8/ORF10. The study suggests potential for developing an optimized antibody cocktail to combat the mutational drift of the Spike protein. This research is part of a $13.3 million agreement with the Department of Defense, supporting Immunome’s COVID therapeutic programs.
Immunome, Inc. (Nasdaq: IMNM) recently appointed Richard Baron to its Board of Directors and Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer. These appointments are anticipated to enhance Immunome's capabilities in antibody discovery and clinical program advancement. Additionally, CEO Purnanand Sarma received TiE Boston's 2020 Lifetime Achievement Award for his contributions to science and entrepreneurship. The press release emphasizes the company's commitment to innovating antibody therapeutics targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced Q3 2020 financial results, highlighting a significant milestone with the completion of its IPO, yielding $44.9 million in gross proceeds. The company aims to advance clinical programs for oncology and COVID-19 treatments, including filing IND applications in 2021. Key financial metrics reveal cash and cash equivalents at $6.7 million and a net loss of $8.4 million, equating to $7.52 per share. The R&D expenses decreased from $2.2 million in Q3 2019 to $1.6 million in Q3 2020, while G&A expenses increased considerably from $0.5 million in the same period.
Immunome, Inc. (Nasdaq: IMNM) has announced the full exercise of the underwriters' option for 487,500 additional shares at $12.00 each, raising approximately $5.9 million in gross proceeds. This follows their initial public offering, totaling 3,737,500 shares sold and gross proceeds of about $44.9 million before expenses. The offering, effective as of October 1, 2020, enhances Immunome's funding to continue its focus on oncology and infectious diseases, leveraging its innovative memory B cell platform for therapeutic development.
Immunome, Inc. (Nasdaq: IMNM) has announced the pricing of its initial public offering, now upsized to 3,250,000 shares at $12.00 per share, totaling approximately $39.0 million in gross proceeds. This offering includes a 30-day option for underwriters to purchase an additional 487,500 shares. Trading is set to commence on the Nasdaq Capital Market on October 2, 2020, with the offering expected to close on October 6, 2020. Ladenburg Thalmann & Co. and Chardan are the book-running managers.